← Leaderboards
Athe M. Tsibris
Massachusetts General Hospital
$17,945,517
Attributed
$22,443,604
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,286,931 · 11
By mechanism
R01$12,695,709 · 3
P01$8,769,432 · 3
R61$3,206,561 · 1
P30$1,901,097 · 1
R33$1,781,082 · 1
R21$524,000 · 1
Top collaborators
- Daniel R Kuritzkes5 shared
- Ya-Chi Ho4 shared
- Jonathan Li4 shared
- Nina H. Lin3 shared
- Manish Sagar2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Stephanie Jost$7,411,250
- Marcus Altfeld$19,256,149
- Pritha Sen$928,980
- E. Antonio Chiocca$34,514,665
- Galit Alter$32,273,423
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusAntiretroviral TherapyHiv-1CellsParticipantSamplingInfectionPlasmaIn VivoEvolutionProteinsGenomeProductionProvirusesPeripheral Blood Mononuclear CellGenetic TranscriptionPhylogenetic AnalysisBloodLengthImmuneViremiaPressureViralMaintenance
Grant awards (39)
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,700,985
P01 · FY2025 · AI
HIV-2 latency and its reversal$843,234
R01 · FY2025 · AI · contact PI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$791,766
R01 · FY2025 · AI · contact PI
Developmental and Mentoring Core$725,040
P30 · FY2025 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3$494,647
P01 · FY2025 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,681,120
P01 · FY2024 · AI
HIV-2 latency and its reversal$843,234
R01 · FY2024 · AI · contact PI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$791,766
R01 · FY2024 · AI · contact PI
Developmental and Mentoring Core$636,539
P30 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3$473,636
P01 · FY2024 · AI · contact PI
Developmental and Mentoring Core$271,768
P30 · FY2024 · AI · contact PI
Developmental and Mentoring Core$267,750
P30 · FY2024 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,721,792
P01 · FY2023 · AI
HIV-2 latency and its reversal$886,729
R01 · FY2023 · AI · contact PI
The effects of opioid use on HIV-1 reservoir dynamics$883,605
R33 · FY2023 · DA · contact PI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$791,766
R01 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3$486,250
P01 · FY2023 · AI · contact PI
HIV-2 latency and its reversal$222,286
R01 · FY2023 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir$1,739,430
P01 · FY2022 · AI
HIV-2 latency and its reversal$905,874
R01 · FY2022 · AI · contact PI
The effects of opioid use on HIV-1 reservoir dynamics$897,477
R33 · FY2022 · DA · contact PI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$811,645
R01 · FY2022 · AI · contact PI
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3$471,572
P01 · FY2022 · AI · contact PI
HIV-2 latency and its reversal$887,215
R01 · FY2021 · AI · contact PI
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy$821,589
R01 · FY2021 · AI · contact PI
The effects of opioid use on HIV-1 reservoir dynamics$1,066,790
R61 · FY2020 · DA · contact PI
The effects of opioid use on HIV-1 reservoir dynamics$1,057,122
R61 · FY2019 · DA · contact PI
HIV-1 translation efficiency during latency reversal$274,500
R21 · FY2019 · AI · contact PI
The effects of opioid use on HIV-1 reservoir dynamics$1,082,649
R61 · FY2018 · DA · contact PI
HIV-1 reservoir dynamics in the female genital tract$779,891
R01 · FY2018 · AI · contact PI
HIV-1 translation efficiency during latency reversal$249,500
R21 · FY2018 · AI · contact PI
HIV-1 reservoir dynamics in the female genital tract$789,041
R01 · FY2017 · AI · contact PI
HIV-1 reservoir dynamics in the female genital tract$800,349
R01 · FY2016 · AI · contact PI
HIV-1 reservoir dynamics in the female genital tract$810,848
R01 · FY2015 · AI · contact PI
HIV-1 reservoir dynamics in the female genital tract$918,476
R01 · FY2014 · AI · contact PI
Dynamic HIV-1 Escape from CCR5 Antagonism in vito$72,900
K08 · FY2011 · AI · contact PI
Dynamic HIV-1 Escape from CCR5 Antagonism in vito$63,450
K08 · FY2011 · AI · contact PI
Dynamic HIV-1 Escape from CCR5 Antagonism in vito$136,350
K08 · FY2010 · AI · contact PI
Dynamic HIV-1 Escape from CCR5 Antagonism in vito$136,350
K08 · FY2009 · AI · contact PI